bkelly

/Bill Kelly

About Bill Kelly

This author has not yet filled in any details.
So far Bill Kelly has created 1166 blog entries.

MannKind inks deal with United Therapeutics

MannKind Corp. and United Therapeutics Corp. announced Tuesday they have entered into a worldwide exclusive licensing agreement to develop and commercialize a dry powder form of an investigational product being used in clinical trials to treat pulmonary arterial hypertension. Michael Castagna, CEO of MannKind, said the agreement solidifies the company’s commitment to Danbury and, though he did not provide a specific number, is likely to create manufacturing jobs in the area. more

By |September 18th, 2018|News|0 Comments

BioCT partners with UConn on new webinar series

BioCT, in partnership with UConn, announces a new webinar series called:  "A Day in the Life of..." This webinar series is geared toward students who are wondering what types of jobs are available in the bioscience industry in Connecitcut and how to prepare for those jobs. Webinars will also review the types of career path you might consider as well. One webinar will be presented each month, focused on different job topics presented by different companies and/or relating individual experiences. The webinar's focus is to connect talent to the needs of the bioscience industry in Connecticut, not only today but in the future. If you register [...]

By |September 18th, 2018|News|0 Comments

BioCT welcomes new member Azitra

Azitra, Inc. is a preclinical stage biotechnology company combining the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its consumer health and pharmaceutical programs to treat atopic dermatitis, dry skin and targeted orphan indications. more

By |September 18th, 2018|News|0 Comments

Loxo oncology drug gains FDA breakthrough status

Stamford-based Loxo Oncology, which is developing cancer treatments, announced this week that it had gained Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its Loxo-292 drug. “We look forward to working with FDA to streamline the development of Loxo-292 in the two patient populations that have comprised the bulk of our initial clinical trial enrollment,” Loxo CEO Josh Bilenker said in a statement. “Given the many available therapies for non-small-cell lung cancer and medullary thyroid cancer, we are pleased that Loxo-292 has shown encouraging data in ‘refractory’ patients and hope to demonstrate the full potential of this [...]

By |September 18th, 2018|News|0 Comments

Arvinas a leader in protein degradation oncology

Protein degradation has become a hot field in oncology, as new companies look to do better than the original set of therapies that have hit the market. In Arvinas’ case, CEO John Houston has been going after prostate cancer and breast cancer, with their first Phase I for the lead prostate cancer therapy lining up for a start in early 2019. Arvinas gained a considerable amount of attention for two deals with Genentech and Pfizer, which came with a relatively small upfront and big back end numbers. more

By |September 13th, 2018|News|0 Comments

BioCT welcomes new member NorthEast BioLab

NorthEast BioAnalytical Laboratories LLC (NorthEast BioLab) is a boutique contract research organization (CRO) providing tailored solutions to biotechnology and pharmaceutical companies. It has a 15+ years’ distinctive track record of successfully collaborating with emerging disruptors and leading incumbents, as well as with the scientific and academic fraternity across the healthcare sector. more

By |September 13th, 2018|News|0 Comments

Achillion appoints Paul Firuta Chief Operating Officer

Achillion Pharmaceuticals has appointed Paul Firuta to the position of Executive Vice President and Chief Operating Officer, effective immediately. Mr. Firuta, with 27 years of experience successfully building commercial organizations and launching products targeting rare diseases, will assume responsibility for leading Achillion’s commercial strategy and operations, market access, pharmaceutical sciences & manufacturing, project management and patient advocacy. more

By |September 13th, 2018|News|0 Comments

ABCT information sessions scheduled re 2019 cohort

ABCT, the Accelerator for Biosciences in Connecticut, is open to research scientists, engineers, MD's, MBA's faculty, graduate students, post docs, and technologists based in Connecticut who meet certain eligibility requirements. The deadline to apply for the 2019 cohort is October 23 at 5:00 pm. Details of the program ABCT 2018-2019 Application Form Both in-person and online information sessions have been scheduled as follows. Click to register. In-Person:  @ Yale - September 12, 2018 2:00PM @ BioCT Commons - September 13, 2018 4:30PM @ UCONN TIP - September 18, 2018 12:00PM @ UNH - September 20, 2018 1:40PM @ Science Park - September 25, 2018 8:30AM [...]

By |September 13th, 2018|News|0 Comments

BioCT welcomes new member Bioarray Genetics

Bioarray is a biotech company developing gene profiling tests to personalize cancer treatments. Bioarray developed the world’s first stratification test for Triple Negative Breast Cancer Patients, BA100. BA100 keeps approximately 67% of Triple Negative Breast Cancer Patients from an ineffective 4-6 months of standard-of-care chemotherapy. more

By |September 13th, 2018|News|0 Comments

Biohaven closes AstraZeneca licensing deal

Biohaven Pharmaceuticals Inc. has signed a licensing agreement with pharma giant AstraZeneca for a new drug to treat a rare neurodegenerative disease. The drug inhibits MPO, a key driver of oxidative and inflammatory processes, high levels of which have been linked to brain disorders like multiple sclerosis and Alzheimer's disease. more

By |September 13th, 2018|News|0 Comments